Research programme: anti-nucleosome antibodies - Ambrilia Biopharma

Drug Profile

Research programme: anti-nucleosome antibodies - Ambrilia Biopharma

Alternative Names: ANA; ANAs research programme - Procyon; ANsA research programme - Procyon; Anti-nucleosome antibodies research programme - Procyon; Monoclonal antibody 2C5

Latest Information Update: 10 Jul 2013

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Jul 2013 Discontinued - Preclinical for Cancer in Canada prior to 9 July 2013 (parenteral)
  • 09 Jul 2013 Discontinued - Preclinical for Cancer in United Kingdom prior to 9 July 2013 (parenteral)
  • 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top